Business
Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting
Company will debut five-year results from GALE study showing meaningful impact of early and continuous treatment with SYFOVRE® (pegcetacoplan injection)
About this update from Apellis Pharmaceuticals, Inc.
[{"type":"text","content":"Company will debut five-year results from GALE study showing meaningful impact of early and continuous treatment with SYFOVRE® (pegcetacoplan injection) WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that eight abstracts were accepted for oral presentations at the 49th Macula Society Annual Meeting, taking place February 25-28 in San Diego, California. New data to be presented include the comprehensive analysis from the GALE extension study following five years of continuous treatment with SYFOVRE® (pegcetacoplan injection), the most prescribed treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). “We look forward to sharing the five-year results from our GALE extension study, which show the importance of early treatment with SYFOVRE for preserving retinal tissue and delaying disease progression in patients with geographic atrophy,” said Caroline Baumal, M.D., chief medical officer, Apellis. “Backed by the largest GA data set with the longest follow-up, these new findings demonstrate the clinically meaningful impact that SYFOVRE can have for patients living with this devastating disease.” The oral presentation of the GALE data, “Earlier Treatment Yields Better Outcomes: 5-Years of Pegcetacoplan Treatment for Geographic Atrophy Secondary to AMD,” will take place on Friday, February 27 at 11:25 a.m. PT, presented by Dilsher S. Dhoot, M.D. Additional presentations include: OCT-F: AI-Enabled Retinal Function from Structural OCT- Results from OAKS & DERBY – Jay Chhablani – Wednesday, February 25, 5:10 – 5:15 p.m. PTReal-world Pegcetacoplan and Anti-VEGF Treatment Patterns among Patients with Geographic Atrophy – Theodore Leng – Thursday, February 26, 11:18 – 11:23 a.m. PTRetrospective Comparative Analysis of Demographic and Clinical Profiles in Pegcetacoplan-Treated and Untreated Patients With Geographic Atrophy – Nimesh Patel – Thursday, February 26, 11:23 am – 11:28 a.m. PTFactors Affecting Disease Progression and Vision Loss in Geographic Atrophy: Findings from OAKS and DERBY – David Boyer – Friday, February 27, 11:15 – 11:25 a.m. PTFellow Eye Analysis, Including Ellipsoid Zone (EZ) Loss, in Bilateral GA due to AMD: Long-term Data from the OAKS, DERBY, and GALE Studies – Sunir Garg – Friday, February 27, 11:35 – 11:45 a.m. PTCan Vi...